Posted on by ScienceFather
70 / 100
Powered by Rank Math SEO

Dr. Srijan Acharya | Molecular Pharmacology | Excellence in Research

Dr at St. Jude Children’s Research Hospital, United States

Srijan Acharya is a dedicated scientist with expertise in molecular pharmacology and cancer genomics. He is currently a Post-Doctoral Research Fellow at St. Jude Childrenā€™s Research Hospital, focusing on childhood cancer research. With 32 published scientific articles and a total citation count of over 385, his work has contributed significantly to biomarker discovery, receptor pharmacology, and immuno-oncology. His research aims to address therapeutic resistance in pediatric malignancies through small molecule screening. Srijan is fluent in English, Bangla, and Hindi, with basic knowledge of Korean.

Profile

Scholar

šŸŽ“ Education

PhD in Molecular Pharmacology from Chonnam National University, South Korea (2020). M.Sc. in Biotechnology from North South University, Bangladesh (2015). BPHRM in Pharmacy from East West University, Bangladesh (2012). His academic journey has provided a strong foundation in receptor pharmacology and molecular biology, guiding his transition into cancer research.

šŸ’¼ Experience

Post-Doctoral Research Fellow, Pharmacy Department, St. Jude Childrenā€™s Research Hospital, USA (2023-Present). Post-Doctoral Research Fellow, Pathology Department, Mitchell Cancer Institute, USA (2020-2023). Executive Officer, Research and Development, Square Pharmaceutical PLC, Bangladesh (2012-2013). His experience spans academia and industry, with a focus on cancer research, receptor signaling, and small molecule screening.

šŸ† Awards and Honors

Inducted into Sigma Xi, The Scientific Research Honor Society (2023). Recognized in Whoā€™s Who in America by Marquis (2023). Young Investigator Award at AACR conference by AAISCR (2022). Best Presenter Award from China Pharmaceutical University (2021). Global Scholarship from Chonnam National University, Korea (2015). These accolades reflect his significant contributions to molecular pharmacology and cancer research.

šŸ”¬ Research Focus

Srijanā€™s research primarily investigates the role of molecular signaling in cancer, focusing on the interaction of nicotine receptors with GPCRs and their impact on cancer progression. At St. Jude, his work focuses on childhood cancers, particularly Ewing sarcoma and rhabdomyosarcoma. He uses small molecule screening to discover potential therapeutic agents and aims to overcome therapeutic resistance in pediatric cancers.

Conclusion

Srijan Acharya is a highly accomplished and promising researcher whose contributions to cancer pharmacology and molecular biology are noteworthy. His interdisciplinary research approach, combined with his dedication to advancing pediatric oncology, positions him as a leader in the field. With continued mentorship and broader collaborative efforts, Acharya is well poised for even greater achievements, further solidifying his place as an influential scientist in the biomedical community.

šŸ“šPublicationsĀ 

  • Title: Unveiling the intracellular dynamics of Ī±4Ī²2 nAChR-mediated ERK activation through the interplay of arrestin, GĪ²Ī³, and PKCĪ²II
    Year: 2024
    Authors: Dooti K, Acharya S, Wang S, Kim K.M.

 

  • Title: Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer
    Year: 2023
    Authors: Acharya S, Anand S, Khan MA, Zubair H, Srivastava SK, Singh S, Singh AP

 

  • Title: MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer
    Year: 2023
    Authors: Md Khan, S Acharya, S Anand, F Sameeta, P Pramanik, C Keel, S Singh, James E Carter, S Dasgupta, A Singh

 

  • Title: Comparative study of the molecular mechanisms underlying the G protein and Ī²-arrestin-dependent pathways that lead to ERKs activation upon stimulation by dopamine D2 receptor
    Year: 2023
    Authors: Liu H, Acharya S, Sudan SK, Hu L, Wu C, Cao Y, Li H, Zhang X

 

  • Title: Frequent loss of cacna1c, a calcium voltage-gated channel subunit is associated with lung adenocarcinoma progression and poor prognosis
    Year: 2023
    Authors: Dasgupta, S., Acharya, S., Khan, M. A., Pramanik, P., Marbut, S. M., Yunus, F., Galeas, J. N., Singh, S., Singh, A. P., and Dasgupta, S.

 

  • Title: Nicotine causes alternative polarization of macrophages via Src-mediated STAT3 activation: Potential pathobiological implications
    Year: 2022
    Authors: Acharya S, Saranyutanon S, Deshmukh SK, Khan MA, Singh S, Singh AP

 

  • Title: Ī²-Arrestin1 and GRK2 play permissive roles in Src-mediated endocytosis of Ī±4Ī²2 nicotinic acetylcholine receptor
    Year: 2021
    Authors: Acharya S, Kundu D, Kim KM

 

  • Title: Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease
    Year: 2021
    Authors: Acharya S, Kim KM

 

  • Title: Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer
    Year: 2021
    Authors: Miree, O., Srivastava, ā€¦Acharya S.et al.

 

  • Title: Metabotropic signaling cascade involved in Ī±4Ī²2 nicotinic acetylcholine receptor-mediated PKCĪ²II activation
    Year: 2020
    Authors: Acharya S, D. Kundu, H.J. Choi, and K.M. Kim

 

  • Title: Catalpol and Mannitol, Two Components of Rehmannia glutinosa, Exhibit Anticonvulsant Effects Probably via GABAA Receptor Regulation
    Year: 2019
    Authors: Acharya S, Kim M., Botanas C. J., Custodio R. J., Lee H. J., Sayson L. V., Kim H. J.

 

  • Title: Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors
    Year: 2017
    Authors: Paudel S, Acharya S, Yoon G, Kim K.M., & Cheon S.H.

 

Srijan Acharya | Molecular Pharmacology | Excellence in Research

You May Also Like